Recent advances in understanding synaptic abnormalities in Rett syndrome

F1000Research

Volumn 4, Issue , 2015, Pages

  Johnston, Michael ^a   Blue, Mary E ^a   Naidu, Sakkubai ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970984050     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6987.1     Document Type: Review

References (58)

1. Chen L Chen K Lavery LA: MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome. Proc Natl Acad Sci U S A. 2015;112(17):5509-14. 25870282 10.1073/pnas.1505909112 4418849
2. Naidu S Johnston MV: Neurodevelopmental disorders: Clinical criteria for Rett syndrome. Nat Rev Neurol. 2011;7(6):312-4. 21587242 10.1038/nrneurol.2011.64
3. Chapleau CA Larimore JL Theibert A: Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J Neurodev Disord. 2009;1(3):185-96. 19966931 10.1007/s11689-009-9027-6 2788955
4. Tsujimura K Irie K Nakashima H: miR-199a Links MeCP2 with mTOR Signaling and Its Dysregulation Leads to Rett Syndrome Phenotypes. Cell Rep. 2015;12(11):1887-901. 26344767 10.1016/j.celrep.2015.08.028
5. Nectoux J Fichou Y Cagnard N: Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy. J Mol Med (Berl). 2011;89(2):193-202. 21107515 10.1007/s00109-010-0699-x
6. Bahi-Buisson N Nectoux J Girard B: Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant. Neurogenetics. 2010;11(2):241-9. 19806373 10.1007/s10048-009-0220-2
7. Fichou Y Bieth E Bahi-Buisson N: Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2009;73(1):77-8; author reply 78. 19564592 10.1212/01.wnl.0000349658.05677.d7
8. Canitano R: New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr. 2014;2:61. 24999471 10.3389/fped.2014.00061 4064155
9. Naidu S: Rett syndrome: a disorder affecting early brain growth. Ann Neurol. 1997;42(1):3-10. 9225679 10.1002/ana.410420104
10. Glaze DG: Rett syndrome: of girls and mice--lessons for regression in autism. Ment Retard Dev Disabil Res Rev. 2004;10(2):154-8. 15362175 10.1002/mrdd.20030
11. Cooper RA Kerr AM Amos PM: Rett syndrome: critical examination of clinical features, serial EEG and video-monitoring in understanding and management. Eur J Paediatr Neurol. 1998;2(3):127-35. 10726834 10.1016/S1090-3798(98)80028-7
12. de Felice C Maffei S Signorini C: Subclinical myocardial dysfunction in Rett syndrome. Eur Heart J Cardiovasc Imaging. 2012;13(4):339-45. 22113206 10.1093/ejechocard/jer256
13. Jentarra GM Olfers SL Rice SG: Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation. BMC Neurosci. 2010;11:19. 20163734 10.1186/1471-2202-11-19 2836362
14. Nguyen MV Du F Felice CA: MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci. 2012;32(29):10021-34. 22815516 10.1523/JNEUROSCI.1316-12.2012 3461266
15. Landi S Putignano E Boggio EM: The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci Rep. 2011;1:45. 22355564 10.1038/srep00045 3216532
16. Chapleau CA Calfa GD Lane MC: Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol Dis. 2009;35(2):219-33. 19442733 10.1016/j.nbd.2009.05.001 2722110
17. Armstrong DD: Neuropathology of Rett syndrome. J Child Neurol. 2005;20(9):747-53. 16225830 10.1177/08830738050200090901
18. Johnston MV Jeon OH Pevsner J: Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain Dev. 2001;23(Suppl 1):S206-13. 11738874 10.1016/S0387-7604(01)00351-5
19. Ronnett GV Leopold D Cai X: Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol. 2003;54(2):206-18. 12891673 10.1002/ana.10633
20. Hamberger A Gillberg C Palm A: Elevated CSF glutamate in Rett syndrome. Neuropediatrics. 1992;23(4):212-3. 1357572 10.1055/s-2008-1071344
21. Lappalainen R Riikonen RS: High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol. 1996;15(3):213-6. 8916158 10.1016/S0887-8994(96)00218-4
22. Blue ME Naidu S Johnston MV: Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol. 1999;156(2):345-52. 10328941 10.1006/exnr.1999.7030
23. Blue ME Naidu S Johnston MV: Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol. 1999;45(4):541-5. 10211484 10.1002/1531-8249(199904)45:4<541::AID-ANA21>3.0.CO;2-2
24. Horská A Farage L Bibat G: Brain metabolism in Rett syndrome: age, clinical, and genotype correlations. Ann Neurol. 2009;65(1):90-7. 19194883 10.1002/ana.21562 2676876
25. Blue ME Kaufmann WE Bressler J: Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat Rec (Hoboken). 2011;294(10):1624-34. 21901842 10.1002/ar.21380 4122218
26. Blackman MP Djukic B Nelson SB: A critical and cell-autonomous role for MeCP2 in synaptic scaling up. J Neurosci. 2012;32(39):13529-36. 23015442 10.1523/JNEUROSCI.3077-12.2012 3483036
27. Asaka Y Jugloff DG Zhang L: Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006;21(1):217-27. 16087343 10.1016/j.nbd.2005.07.005
28. Dani VS Chang Q Maffei A: Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2005;102(35):12560-5. 16116096 10.1073/pnas.0506071102 1194957
29. Zhang L He J Jugloff DG: The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus. 2008;18(3):294-309. 18058824 10.1002/hipo.20389
30. Maliszewska-Cyna E Bawa D Eubanks JH: Diminished prevalence but preserved synaptic distribution of N-methyl- D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience. 2010;168(3):624-32. 20381590 10.1016/j.neuroscience.2010.03.065
31. Magistretti PJ Pellerin L: Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci. 1999;354(1387):1155-63. 10466143 10.1098/rstb.1999.0471 1692634
32. Zhou X Hollern D Liao J: NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013;4(3):e560. 23538441 10.1038/cddis.2013.82 3615746
33. Maezawa I Jin LW: Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci. 2010;30(15):5346-56. 20392956 10.1523/JNEUROSCI.5966-09.2010
34. Guy J Hendrich B Holmes M: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27(3):322-6. 11242117 10.1038/85899
35. Jin LW Horiuchi M Wulff H: Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J Neurosci. 2015;35(6):2516-29. 25673846 10.1523/JNEUROSCI.2778-14.2015 4323531
36. Okabe Y Takahashi T Mitsumasu C: Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome. PLoS One. 2012;7(4):e35354. 22532851 10.1371/journal.pone.0035354 3332111
37. Lioy DT Garg SK Monaghan CE: A role for glia in the progression of Rett's syndrome. Nature. 2011;475(7357):497-500. 21716289 10.1038/nature10214 3268776
38. Russell JC Blue ME Johnston MV: Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to excitotoxicity and hypoxia. Neuroscience. 2007;150(3):563-74. 17997046 10.1016/j.neuroscience.2007.09.076 2227264
39. Azuma S Kodama T Honda K: State-dependent changes of extracellular glutamate in the medial preoptic area in freely behaving rats. Neurosci Lett. 1996;214(2-3):179-82. 8878113 10.1016/0304-3940(96)12918-9
40. Johnston MV Ammanuel S O'Driscoll C: Twenty-four hour quantitative-EEG and in-vivo glutamate biosensor detects activity and circadian rhythm dependent biomarkers of pathogenesis in Mecp2 null mice. Front Syst Neurosci. 2014;8:118. 25018705 10.3389/fnsys.2014.00118 4072927
41. Chao HT Chen H Samaco RC: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468(7321):263-9. 21068835 10.1038/nature09582 3057962
42. Kang SK Kim ST Johnston MV: Temporal- and Location-Specific Alterations of the GABA Recycling System in Mecp2 KO Mouse Brains. J Cent Nerv Syst Dis. 2014;6:21-8. 24737935 10.4137/JCNSD.S14012 3981570
43. El-Khoury R Panayotis N Matagne V: GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice. PLoS One. 2014;9(3):e92169. 24667344 10.1371/journal.pone.0092169 3965407
44. Nelson SB Valakh V: Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. Neuron. 2015;87(4):684-98. 26291155 10.1016/j.neuron.2015.07.033 4567857
45. Krishnan K Wang BS Lu J: MeCP2 regulates the timing of critical period plasticity that shapes functional connectivity in primary visual cortex. Proc Natl Acad Sci U S A. 2015;112(34):E4782-91. 26261347 10.1073/pnas.1506499112 4553776
46. Fagiolini M Fritschy JM Low K: Specific GABAA circuits for visual cortical plasticity. Science. 2004;303(5664):1681-3. 15017002 10.1126/science.1091032
47. Durand S Patrizi A Quast KB: NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron. 2012;76(6):1078-90. 23259945 10.1016/j.neuron.2012.12.004 3733788
48. He LJ Liu N Cheng TL: Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. Nat Commun. 2014;5:5036. 25297674 10.1038/ncomms6036
49. Kron M Howell CJ Adams IT: Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci. 2012;32(40):13860-72. 23035095 10.1523/JNEUROSCI.2159-12.2012 3500840
50. Slikker W Jr Liu F Rainosek SW: Ketamine-Induced Toxicity in Neurons Differentiated from Neural Stem Cells. Mol Neurobiol. 2015;52(2):959-69. 26055230 10.1007/s12035-015-9248-5
51. McDonald JW Johnston MV: Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Brain Res Rev. 1990;15(1):41-70. 2163714 10.1016/0165-0173(90)90011-C
52. Khwaja OS Ho E Barnes KV: Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111(12):4596-601. 24623853 10.1073/pnas.1311141111 3970488
53. Banerjee A Castro J Sur M: Rett syndrome: genes, synapses, circuits, and therapeutics. Front Psychiatry. 2012;3:34. 22586411 10.3389/fpsyt.2012.00034 3346964
54. Chen RZ Akbarian S Tudor M: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001;27(3):327-31. 11242118 10.1038/85906
55. Tropea D Giacometti E Wilson NR: Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106(6):2029-34. 19208815 10.1073/pnas.0812394106 2644158
56. Castro J Garcia RI Kwok S: Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A. 2014;111(27):9941-6. 24958891 10.1073/pnas.1311685111 4103342
57. Deogracias R Yazdani M Dekkers MP: Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2012;109(35):14230-5. 22891354 10.1073/pnas.1206093109 3435172
58. Guo W Tsujimura K Otsuka IM: VPA alleviates neurological deficits and restores gene expression in a mouse model of Rett syndrome. PLoS One. 2014;9(6):e100215. 24968028 10.1371/journal.pone.0100215 4072629